A5080009153- Multiple Sclerosis Research Studies
- Sphingolipid Metabolism and Signaling
- Infectious Diseases and Mycology
- Research on Leishmaniasis Studies
- Polyomavirus and related diseases
- Plant Pathogenic Bacteria Studies
- Myasthenia Gravis and Thymoma
- Radiopharmaceutical Chemistry and Applications
- Monoclonal and Polyclonal Antibodies Research
- Lysosomal Storage Disorders Research
- Antifungal resistance and susceptibility
- Mycobacterium research and diagnosis
- Pregnancy and Medication Impact
- Psoriasis: Treatment and Pathogenesis
- Peripheral Neuropathies and Disorders
Janssen (Belgium)
2020-2022
Actelion (Switzerland)
2014-2022
University of Ottawa
2022
Charles University
2022
Sapienza University of Rome
2022
Karolinska Institutet
2022
Janssen (Switzerland)
2021-2022
Ottawa Hospital
2022
Ottawa Hospital Research Institute
2022
To our knowledge, the Oral Ponesimod Versus Teriflunomide In Relapsing Multiple Sclerosis (OPTIMUM) trial is first phase 3 study comparing 2 oral disease-modifying therapies for relapsing multiple sclerosis (RMS).
To evaluate the dose-response relationship of 10, 20, and 40 mg ponesimod long-term efficacy safety 20 using an analysis combined data from phase 2 Core Extension studies in patients with relapsing-remitting multiple sclerosis (RRMS).In study, 464 were randomized (1:1:1:1): placebo (n = 121), 10 108), 116), or 119) once daily for 24 weeks. Patients who completed study transitioned into which had treatment period 1 (TP1; up to 96 weeks) TP2 TP3 (up 432 weeks). The dose was discontinued due...
Abstract The efficacy of ponesimod and teriflunomide for the treatment relapsing multiple sclerosis (MS) was compared in a randomized phase III trial. This study explores exposure‐response (E‐R) relationships end points (annualized relapse rate [ARR] combined unique active lesions [CUALs]) observed this E‐R were described using nonlinear mixed effects models count data. effect baseline covariates (demography prognostic factors) also explored. Ponesimod 20 mg reduced ARR (primary point) by...
<h3>Objective</h3> We describe Vivacity-MG3. our pivotal Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Nipocalimab Administered Adults With gMG (NCT04951622). <h3>Background</h3> is a high affinity, fully human, aglycosylated, effectorless IgG1 anti FcRn monoclonal antibody that targets neonatal Fc receptor (FcRn) with thereby lowering IgG pathogenic antibodies in autoimmune...
Wednesday, April 29April 14, 2020Free AccessEfficacy Outcome Measures of Oral Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study (3972)Robert Fox, Ludwig Kappos, Michel Burcklen, Mark Freedman, Eva Havrdová, Brian Hennessy, Reinhard Hohlfeld, … Show All , Fred Lublin, Xavier Montalban, Carlo Pozzilli, Tatiana Scherz, Philippe Linscheid, Magdalena Pirozek-Lawniczek,...
Evaluate the long-term efficacy and safety of ponesimod in patients with relapsing-remitting multiple sclerosis (RRMS).
Monday, April 27April 14, 2020Free AccessSafety and Tolerability of Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study (1770)Till Sprenger, Michel Burcklen, Mark S. Freedman, Robert Fox, Eva K. Havrdová, Brian Hennessy, Reinhard Hohlfeld, … Show All , Fred Lublin, Xavier Montalban, Carlo Pozzilli, Andrea Vaclavkova, Tatiana Scherz, Philippe Linscheid, Magdalena...
In the OPTIMUM study, patients with relapsing multiple sclerosis (MS) received ponesimod (20mg) or teriflunomide (14mg) over 108 weeks. Here we report on post-treatment relapse activity.